David Gate

Director, Abrams Research Center, Northwestern Neurology. The Gate lab studies the immune system in neurodegenerative diseases.

[David Gate @DGateLab]

Excited to share our latest work on ALS neuroimmunology, published today in @NatureNeuro https://t.co/Ewdf2a4ge2

[The Colonna Lab @TheColonnaLab]

New paper from the Colonna lab! cMAF is a key regulator of BAM identity and drives communication with brain arteries via IGF1. We show that this cMAF-dependent program in BAMs supports cerebrovascular function in mice and is protective against AD.

https://t.co/IEzw44YYdB

[David Gate @DGateLab]

Really amazing collaboration with such an excellent team of researchers. My lab was fortunate to play a part in this fantastic work.

[Julia Belk @juliabelk]

The transcription factor MAF is known from human genetics to be important in Alzheimer’s disease, but its precise function within the brain has been unclear.

Our latest, out today in @CellCellPress, dissects the role of MAF in brain macrophages. 1/

https://t.co/5jtMEvvNMd

[David Gate @DGateLab]

@nottalexi @sj_marzi @HolstegeHenne What a great team! Congrats!

[Science Magazine @ScienceMagazine]

Genetically altered astrocytes that express chimeric antigen receptors offer a promising immunotherapy system capable of clearing accumulations of amyloid-β in the brains of mice—a hallmark pathological feature of #AlzheimersDisease, according to a new study in Science.

📄: https://t.co/jMTIzVznEV
#SciencePerspective: https://t.co/h1aL5tdltT

[Center for Human Immunobiology @immunology_nu]

Congrats @DGateLab on having one of the Top 3 Episodes of Breakthroughs Podcast in 2025! If you haven't listened you can do so and learn more here; https://t.co/MkdqLkLVnf

[François Chollet @fchollet]

Key to research success: ambition in vision, but pragmatism in execution. You must be guided by a long-term, ambitious goal that addresses a fundamental problem, rather than chasing incremental gains on established benchmarks. Yet, your progress should be grounded by tractable short-term metrics/tasks that force you to constantly make contact with reality.

[Tempus @TempusAI]

We are proud to announce a collaboration with @ARC_Neuro at Northwestern University Feinberg School of Medicine to harness AI for rapid discovery and innovation in Alzheimer’s disease research. Using Lens, the Center and Tempus teams will work together to uncover genomic patterns that have the potential to advance the understanding of Alzheimer’s disease, investigate the gene and cell types affected, enable the development of new therapeutics, and accelerate the creation of novel clinical applications.

Learn more: https://t.co/m0ZEWjK9qc

[Hamilton Oh @hammy_oh]

I am excited to present our new study out in @NatureMedicine where we discover a novel synaptic protein biomarker to predict if and when someone will get Alzheimer’s disease dementia. Part 2/3 from my PhD work in the @wysscoray lab. 🧵1/12

Full study 🔗: https://t.co/yg8lmRXuTN

[David Gate @DGateLab]

The Gate lab is fortunate to have such a talented scientist like @TerryRSuk joining us soon. Check out his impressive work!

[Terry R Suk @TerryRSuk]

We’re happy to share that our labs first #ALS and #FTD study “A stress-dependent TDP-43 SUMOylation program preserves neuronal function” is now online @MolNeuro!
https://t.co/fqv8ivFde4

[Alzforum @alzforum]

In brains of people immunized against Aβ, postmortem omics reveal microglial plaque clearing pathways. @NorthwesternU https://t.co/aKkrYJUioJ

[David Gate @DGateLab]

It’s quite an experience to have some of your favorite labs like ⁦@TheColonnaLab⁩ and ⁦@Haass_Lab⁩ comment on your lab’s research. Great reporting by Alzforum! https://t.co/vtERMRGhyU

[David Gate @DGateLab]

This Northwestern Breakthroughs podcast nicely encapsulates our study. The host does a great job leading the discussion for the lay audience to digest our work. I hope this allows people to better understand the results and impact of this study. https://t.co/9v3MwmIr68

[David Gate @DGateLab]

@JustinPerryPhD @jonykipnis @ARC_Neuro You both make good points! I really appreciate the input.

[David Gate @DGateLab]

@jonykipnis @WashU @washumedicine Congrats! What a team!

[David Gate @DGateLab]

@TheIbrahimLab @ARC_Neuro @LynnOlst Thank you, my friend!

[David Gate @DGateLab]

This video describes the findings from our recent study conducted at ⁦@ARC_Neuro⁩. In the video, lead author ⁦@LynnOlst⁩ and I discuss the findings and their implications for Alzheimer’s disease. https://t.co/qUZbFpo5FZ

[David Gate @DGateLab]

https://t.co/rqLMHyGrEq

[David Gate @DGateLab]

Big day today!

[Abrams Research Center on Neurogenomics @ARC_Neuro]

アルツハイマー病の治療は脳自身のクリーンアップクルーにあるかもしれません https://t.co/jpqYHXZ0oN

[Lynn van Olst @LynnOlst]

Excited to share our latest @NatureMedicine study from our new center @ARC_Neuro! 🧠✨ Using spatial transcriptomics & scRNA-seq, we uncover how Aβ-targeting immunotherapies shape microglial responses in AD patient brains.

A thread with our key findings is below! 🧵(1/15)